Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2025)
Historic Total Current Liabilities for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $86.5 million.
- Nurix Therapeutics' Total Current Liabilities fell 978.88% to $86.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $86.5 million, marking a year-over-year decrease of 978.88%. This contributed to the annual value of $86.5 million for FY2025, which is 978.88% down from last year.
- Per Nurix Therapeutics' latest filing, its Total Current Liabilities stood at $86.5 million for Q4 2025, which was down 978.88% from $82.4 million recorded in Q3 2025.
- Nurix Therapeutics' 5-year Total Current Liabilities high stood at $95.9 million for Q4 2024, and its period low was $46.8 million during Q2 2021.
- For the 5-year period, Nurix Therapeutics' Total Current Liabilities averaged around $73.0 million, with its median value being $72.5 million (2022).
- As far as peak fluctuations go, Nurix Therapeutics' Total Current Liabilities surged by 5512.13% in 2022, and later crashed by 978.88% in 2025.
- Quarter analysis of 5 years shows Nurix Therapeutics' Total Current Liabilities stood at $66.3 million in 2021, then rose by 6.64% to $70.7 million in 2022, then grew by 23.07% to $87.0 million in 2023, then grew by 10.23% to $95.9 million in 2024, then decreased by 9.79% to $86.5 million in 2025.
- Its Total Current Liabilities was $86.5 million in Q4 2025, compared to $82.4 million in Q3 2025 and $75.6 million in Q2 2025.